Global RDC Drugs Market Strategic Research Report

Scope of the Report

The global RDC Drugs market size is predicted to grow from US$ 11,040 million in 2025 to US$ 20,030 million in 2032; it is expected to grow at a CAGR of 9.0% from 2026 to 2032.

RDC (Radiopharmaceutical Drug Conjugate) drugs represent a class of precision therapeutic or diagnostic agents formed by linking molecules capable of targeted recognition with radionuclides via chelators or chemical linkers. Their core mechanism relies on "targeted delivery combined with localized radioactive killing or imaging" to achieve highly selective treatment or visualization of tumors or specific lesions—such as in PSMA-targeted therapy for prostate cancer or the management of neuroendocrine tumors. This field is currently a key area of ​​development in nuclear medicine and precision oncology.

In terms of the industry value chain, the upstream sector encompasses the production of medical radioisotopes, the supply of stable isotopes, the provision of chemical materials (chelators and linkers), and the R&D of targeting ligands. The midstream sector consists of companies dedicated to R&D and formulation, handling radionuclide labeling processes, quality control, GMP-compliant radiopharmaceutical preparation, and the logistics of cold-chain or decay-in-storage management. The downstream sector comprises hospital nuclear medicine departments, oncology centers, and PET/SPECT diagnostic and radiotherapy facilities, where patient administration, imaging, and therapeutic applications take place; this sector operates within a robust regulatory framework that imposes strict industry constraints.

Regarding future prospects, the RDC drug sector is in the early stages of a global boom, driven by the rising demand for precision oncology, the maturation of radionuclide supply chains, and the widespread adoption of the "theranostics" (combined diagnosis and therapy) model. Future growth is expected to stem from expanded indications for prostate cancer, neuroendocrine tumors, breast cancer, and other solid tumors, while alpha-radionuclide therapies promise to drive a new wave of technological advancement. Characterized by high barriers to entry, rapid growth, and high unit prices, the industry is expected to continue attracting major pharmaceutical companies and nuclear technology firms.

This report presents a comprehensive overview of the global RDC Drugs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Target Ligand Types

• Antibody-Drug Conjugates (ARC)
• Peptide-Drug Conjugates (PRC)
• Small Molecule-Drug Conjugates (SMRC)

Segment by Medical Uses

• Diagnostic RDCs
• Therapeutic RDCs

Segment by Therapeutic Radionuclide Properties

• β-Nuclear Therapy
• α-Nuclear Therapy

Segment by players, this report covers

• Novartis
• Bayer
• AstraZeneca
• Eli Lilly
• Bristol-Myers Squibb
• Johnson & Johnson
• Grand Pharmaceutical Group
• China Isotope & Radiation Corporation
• Dongcheng Pharmaceutical
• Hengrui Medicine
• Xiantong Pharmaceutical
• Bivision
• SmartNuclide
• Full-Life Technologies
• Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
• Nuoyu Pharmaceutical

Segment by Application

• Prostate Cancer
• Neuroendocrine Tumors
• Liver Cancer
• Kidney Cancer
• Bone Metastases
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global RDC Drugs market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Prostate Cancer, Neuroendocrine Tumors, Liver Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact